Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (OSII-TTP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00978471
Recruitment Status : Active, not recruiting
First Posted : September 17, 2009
Last Update Posted : December 2, 2016
Information provided by (Responsible Party):
Centre Leon Berard

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2017
  Estimated Study Completion Date : December 2018
Rialland F.Treatment and outcome of relapsed osteosarcoma:experience of the societe française des cancers de l'enfant.(in press). 2008. Ref type:in press
Gelderblom H, Sydes MR, Morgan RC, Hogendoorn PC, Lewis IJ, Nooij MA, Taminiau AH, and whelan J. Survival after reccurent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled trials.J Clin Oncol26.20-5-2008
Leary SE,Billups A, Watkins A, Wu J, Poe D, Neel MN, Rao BN and Daw NC.Survival of pediatric patients after relapsed osteosarcoma:The St.Jude Children's Research Hospital experience.JOclin Oncol 26.20-5-2008
Beron G, Euler A, winkley K.pulmonary metastase from osteogenic sarcoma: Complete resection and effective chemotherapy contributing to improved prognosis.Eur Paediatr Haematol Oncol 1985; 2:77-85
Kaplan EL MP.Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958